Treatment of lung metastases in prostate cancer – case reports

05/2021

MUDr. Eva Kindlová

Radioterapeutická a onkologická klinika 3. LF UK a FN Královské Vinohrady, Praha

SUMMARY

Prostate cancer is one of the most common cancers in men. Approximately 20 % of diagnosed patients had already developed metastases, in others the tumor may generalize after the locoregional treatment. The most frequent are bone and lymph nodes metastases, less frequented sites of metastases are lungs, liver, and other organs. The ways of treatment depend on whether the tumor is metastatic hormone-naive prostate cancer (mHSPC) or metastatic castration-resistant prostate cancer (mCRPC). Both local and systemic therapies are possible for treating lung metastases. Modalities of local therapy are surgical therapy and radiotherapy; hormone therapy, chemotherapy and ARTA therapy can be administered as systemic therapy. It is necessary to choose the optimal sequence of modalities and even use several lines of therapy to reach the best response. That can result in significant improvement of patienťs life expectancy and his quality of life as well.

Key words

metastatic castration-resistant prostate cancer, metastatic hormone-naive prostate cancer, ARTA therapy